Matrivax Research & Development Corporation is a start-up biotechnology company located in Boston, MA., USA. The company was founded by Dr. John Mekalanos, of Harvard Medical School, and Dr. Yichen Lu, of Harvard School of Public Health. Matrivax was incorporated in October 2007 and seed funded by Dr. Gerald Chan of Morningside Ventures. Matrivax has exclusively licensed Protein Capsular Matrix Vaccine (PCMV) technology, a platform that enables a simplified manufacturing process to produce polysaccharide based vaccines against Streptococcus pneumoniae, Neisseria menigitidis, Salmonella Typhi, Clostridium difficile, and others. PCMV technology has the potential to transform the current, complex, and expensive polysaccharide-protein conjugate vaccine manufacture process to a more straightforward, inexpensive process. The Matrivax R&D headquarters are located in Boston, MA. Matrivax has entered into a strategic alliance with Vaccine Technology Inc. (VTI) in Haikou, China for vaccine process development.